Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 11:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–117 of 117 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Acute Bacterial Infections Clear all
Completed Phase 4 Interventional Results available

Development of a New Critical Pathway for Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI)

NCT03233438
View directory record Official record
Conditions
Bacterial Infections, Acute Bacterial Skin and Skin Structure Infection
Interventions
Dalbavancin, Usual Care
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 18, 2020 · Synced Oct 20, 2026, 11:41 PM EDT
Terminated Phase 3 Interventional

DB289 Versus TMP-SMX for the Treatment of Acute Pneumocystis Jiroveci Pneumonia (PCP)

NCT00302341
View directory record Official record
Conditions
Pneumonia, Interstitial Plasma Cell, Pneumocystis Carinii Pneumonia, Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions
Pafuramidine maleate (DB289), Trimethoprim-Sulfamethoxazole (TMP-SMX)
Drug
Lead sponsor
Immtech Pharmaceuticals, Inc
Industry
Eligibility
13 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
7
States / cities
San Francisco, California • Chicago, Illinois • Detroit, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2013 · Synced Oct 20, 2026, 11:41 PM EDT
Completed Not applicable Interventional Results available

Short (5 Days) Versus Long (14 Days) Duration of Antimicrobial Therapy for Acute Bacterial Sinusitis in Children

NCT01166945
View directory record Official record
Conditions
Sinusitis
Interventions
Amoxicillin-Potassium Clavulanate Combination, Placebo
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
1 Year to 10 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
2
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 10, 2019 · Synced Oct 20, 2026, 11:41 PM EDT
Completed Phase 2 Interventional Results available

Pharmacokinetic Study of Oral Gepotidacin (GSK2140944) in Subjects With Uncomplicated Urinary Tract Infection (Acute Cystitis)

NCT03568942
View directory record Official record
Conditions
Infections, Bacterial
Interventions
Gepotidacin
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
La Mesa, California
Source: ClinicalTrials.gov public record
Updated Jun 29, 2020 · Synced Oct 20, 2026, 11:41 PM EDT
Completed Phase 3 Interventional Results available

Ceftobiprole in the Treatment of Patients With Acute Bacterial Skin and Skin Structure Infections

NCT03137173
View directory record Official record
Conditions
Acute Bacterial Skin and Skin Structure Infections
Interventions
ceftobiprole medocaril, vancomycin+aztreonam
Drug
Lead sponsor
Basilea Pharmaceutica
Industry
Eligibility
18 Years and older
Enrollment
679 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
16
States / cities
Anaheim, California • Chula Vista, California • Fresno, California + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 20, 2026, 11:41 PM EDT
Completed Phase 3 Interventional Results available

Study of Oral Oteseconazole (VT-1161) for Acute Yeast Infections in Patients With Recurrent Yeast Infections

NCT03840616
View directory record Official record
Conditions
Recurrent Vulvovaginal Candidiasis
Interventions
Oteseconazole (VT-1161) 150mg capsule, Fluconazole 150mg capsule, Placebo
Drug
Lead sponsor
Mycovia Pharmaceuticals Inc.
Industry
Eligibility
12 Years and older · Female only
Enrollment
219 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
33
States / cities
Tucson, Arizona • Encino, California • Los Angeles, California + 30 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2022 · Synced Oct 20, 2026, 11:41 PM EDT
Completed Phase 3 Interventional Results available

A Study of Safety and Efficacy of MK-1986 (Tedizolid Phosphate) and Comparator in Participants From Birth to Less Than 12 Years of Age With Acute Bacterial Skin and Skin Structure Infections (MK-1986-018)

NCT03176134
View directory record Official record
Conditions
Acute Bacterial Skin and Skin Structure Infections
Interventions
Tedizolid phosphate, Comparator
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
1 Day to 11 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
8
States / cities
San Diego, California • Chicago, Illinois • Detroit, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2025 · Synced Oct 20, 2026, 11:41 PM EDT
Terminated Phase 4 Interventional

Imipenem/Cilastatin/Relebactam Pharmacokinetics, Safety, and Outcomes in Adults and Adolescents With Cystic Fibrosis

NCT05561764
View directory record Official record
Conditions
Cystic Fibrosis, Pneumonia, Bacterial
Interventions
Imipenem/Cilastatin/Relebactam
Drug
Lead sponsor
Hartford Hospital
Other
Eligibility
12 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
3
States / cities
Los Angeles, California • Hartford, Connecticut • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 17, 2024 · Synced Oct 20, 2026, 11:41 PM EDT
Terminated Phase 2 Interventional

NLA101 in Adults Receiving High Dose Chemotherapy for AML

NCT03301597
View directory record Official record
Conditions
Leukemia, Myeloid, Acute
Interventions
NLA101, Standard of Care (SOC) chemotherapy
Biological · Drug
Lead sponsor
Nohla Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
25
States / cities
La Jolla, California • Los Angeles, California • Sacramento, California + 19 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2021 · Synced Oct 20, 2026, 11:41 PM EDT
Terminated Not applicable Interventional Results available

Asymptomatic Colonization With S. Aureus After Therapy With Linezolid or Clindamycin for Acute Skin Infections

NCT01619410
View directory record Official record
Conditions
Skin Diseases, Bacterial, Abscess
Interventions
Linezolid, Clindamycin
Biological
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
2
States / cities
Atlanta, Georgia • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 8, 2019 · Synced Oct 20, 2026, 11:41 PM EDT
Completed Phase 2 Interventional Results available

Dose-Ranging Study of GSK2140944 in the Treatment of Subjects With Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure Infections

NCT02045797
View directory record Official record
Conditions
Infections, Bacterial
Interventions
GSK2140944 Lyophile, GSK2140944 Capsules
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
30
States / cities
Phoenix, Arizona • Anaheim, California • Chula Vista, California + 25 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2017 · Synced Oct 20, 2026, 11:41 PM EDT
Completed Phase 3 Interventional Results available

Single Dose vs. Two Dose Regimen of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections

NCT02127970
View directory record Official record
Conditions
Abscess, Wound Infection, Surgical Site Infection, Cellulitis
Interventions
Dalbavancin, Dalbavancin-matching Placebo
Drug
Lead sponsor
Durata Therapeutics Inc., an affiliate of Allergan plc
Industry
Eligibility
18 Years to 85 Years
Enrollment
698 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
25
States / cities
Montgomery, Alabama • Anaheim, California • Long Beach, California + 18 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2018 · Synced Oct 20, 2026, 11:41 PM EDT
Completed Phase 2 Interventional

RADIANT: CD101 vs Standard of Care in Subjects With Acute Vaginal Yeast Infections

NCT02733432
View directory record Official record
Conditions
Candidiasis, Vulvovaginal, Mycoses, Yeast Infection, Moniliasis, Vulvovaginal, Vaginitis, Monilial
Interventions
CD101 Vaginal Gel (3%), CD101 External gel (1%), CD101 Vaginal Ointment (6%), CD101 External ointment (1%), Fluconazole
Drug
Lead sponsor
Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older · Female only
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
24
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2020 · Synced Oct 20, 2026, 11:41 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects With Acute Vulvovaginal Candidiasis (VANISH 303)

NCT03734991
View directory record Official record
Conditions
Candida Vulvovaginitis
Interventions
Ibrexafungerp, Placebo
Drug
Lead sponsor
Scynexis, Inc.
Industry
Eligibility
12 Years and older · Female only
Enrollment
376 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
25
States / cities
Birmingham, Alabama • Phoenix, Arizona • San Diego, California + 20 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2021 · Synced Oct 20, 2026, 11:41 PM EDT
Recruiting Phase 4 Interventional

Pharmacokinetic Analysis of Cefiderocol in Patients With Acute Burn Injuries

NCT07465432
View directory record Official record
Conditions
Drug Clearance After Severe Burn Injury
Interventions
Cefiderocol
Drug
Lead sponsor
University of Tennessee
Other
Eligibility
18 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Oct 20, 2026, 11:41 PM EDT
Completed Phase 2 Interventional Results available

Pharmacokinetics of Posaconazole Prophylaxis in Acute Leukemia

NCT00936117
View directory record Official record
Conditions
Leukemia, Fungal Infection
Interventions
Posaconazole
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 27, 2019 · Synced Oct 20, 2026, 11:41 PM EDT
Completed Phase 2Phase 3 Interventional

Safety and Efficacy Study of Ceftaroline Versus a Comparator in Pediatric Subjects With Complicated Skin Infections

NCT01400867
View directory record Official record
Conditions
Infections, Pediatrics
Interventions
Ceftaroline fosamil, Vancomycin +/- Aztreonam or Cefazolin +/- Aztreonam, Cephalexin or Clindamycin or Linezolid
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
2 Months to 17 Years
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
28
States / cities
Phoenix, Arizona • Orange, California • San Diego, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2015 · Synced Oct 20, 2026, 11:41 PM EDT
Completed Phase 2 Interventional Results available

A Study to Assess Objective Endpoint Measurements of Response in Bacterial Skin Infections

NCT01283581
View directory record Official record
Conditions
Skin and Subcutaneous Tissue Bacterial Infections
Interventions
Delafloxacin, Linezolid, Vancomycin
Drug
Lead sponsor
Melinta Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
31
States / cities
Mobile, Alabama • Montgomery, Alabama • Buena Park, California + 27 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2019 · Synced Oct 20, 2026, 11:41 PM EDT
Terminated Phase 3 Interventional

Moxifloxacin in Preventing Bacterial Infections in Patients Who Have Undergone Donor Stem Cell Transplant

NCT00324324
View directory record Official record
Conditions
Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Infection, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Neuroblastoma, Ovarian Cancer, Testicular Germ Cell Tumor
Interventions
moxifloxacin hydrochloride, Placebo
Drug
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years to 120 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 9, 2017 · Synced Oct 20, 2026, 11:41 PM EDT
Completed Phase 2 Interventional Results available

TNP-2092 to Treat Acute Bacterial Skin and Skin Structure Infection

NCT03964493
View directory record Official record
Conditions
Skin and Subcutaneous Tissue Bacterial Infections, Gram-Positive Bacterial Infections
Interventions
TNP-2092, Vancomycin
Drug
Lead sponsor
TenNor Therapeutics Limited
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Dec 1, 2023 · Synced Oct 20, 2026, 11:41 PM EDT
Completed No phase listed Observational

Blood Volume Assessment in COVID-19 and Bacterial Sepsis

NCT04517695
View directory record Official record
Conditions
Covid19, Acute Respiratory Distress Syndrome, Bacterial Sepsis, Bacterial Infections
Interventions
BVA-100, Transpulmonary Thermodilution (TPTD), Sublingual Microcirculation
Device
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 95 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
3
States / cities
Bethesda, Maryland • New York, New York • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Oct 20, 2026, 11:41 PM EDT